Calif. molecular Dx firm could bring in $1.9M from stock sale

09/23/2013 | GenomeWeb Daily News (free registration)

Response Genetics hopes to secure $1.9 million in a direct offering of shares. The Los Angeles molecular diagnostics company will use the money to expedite integration of the Tissue of Origin assay it acquired from Pathwork Diagnostics. The test has FDA clearance for identifying undifferentiated, poorly differentiated and metastatic cancers.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC